AAAAAA

   
Results: 1-13 |
Results: 13
Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
Authors: Casimiro, DR Tang, AM Perry, HC Long, RS Chen, MC Heidecker, GJ Davies, ME Freed, DC Persaud, NV Dubey, S Smith, JG Havlir, D Richman, D Chastain, MA Simon, AJ Fu, TM Emini, EA Shiver, JW
Citation: Dr. Casimiro et al., Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene, J VIROLOGY, 76(1), 2002, pp. 185-194
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3099-3102
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3103-3106
Combinatorial synthesis of CCR5 antagonists
Authors: Willoughby, CA Berk, SC Rosauer, KG Degrado, S Chapman, KT Gould, SL Springer, MS Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, EA
Citation: Ca. Willoughby et al., Combinatorial synthesis of CCR5 antagonists, BIOORG MED, 11(24), 2001, pp. 3137-3141
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
Authors: Dorn, CP Finke, PE Oates, B Budhu, RJ Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Cp. Dorn et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 259-264
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes
Authors: Finke, PE Meurer, LC Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 265-270
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
Authors: Finke, PE Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Gould, SL DeMartino, JA Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes, BIOORG MED, 11(18), 2001, pp. 2475-2479
Reliability of C-min: Inhibitory concentration ratios - Reply
Authors: Condra, JH Petropoulos, CJ Ziermann, R Schleif, WA Shivaprakash, M Emini, EA
Citation: Jh. Condra et al., Reliability of C-min: Inhibitory concentration ratios - Reply, J INFEC DIS, 183(6), 2001, pp. 993-994
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
Authors: Barouch, DH Santra, S Schmitz, JE Kuroda, MJ Fu, TM Wagner, W Bilska, M Craiu, A Zheng, XX Krivulka, GR Beaudry, K Lifton, MA Nickerson, CE Trigona, WL Punt, K Freed, DC Guan, LM Dubey, S Casimiro, D Simon, A Davies, ME Chastain, M Strom, TB Gelman, RS Montefiori, DC Lewis, MG Emini, EA Shiver, JW Letvin, NL
Citation: Dh. Barouch et al., Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination, SCIENCE, 290(5491), 2000, pp. 486-492
X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - An initial glance of the viral DNA binding platform
Authors: Chen, ZG Yan, YW Munshi, S Li, Y Zugay-Murphy, J Xu, B Witmer, M Felock, P Wolfe, A Sardana, V Emini, EA Hazuda, D Kuo, LC
Citation: Zg. Chen et al., X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - An initial glance of the viral DNA binding platform, J MOL BIOL, 296(2), 2000, pp. 521-533
Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors
Authors: Dorsey, BD McDonough, C McDaniel, SL Levin, RB Newton, CL Hoffman, JM Darke, PL Zugay-Murphy, JA Emini, EA Schleif, WA Olsen, DB Stahlhut, MW Rutkowski, CA Kuo, LC Lin, JH Chen, IW Michelson, SR Holloway, MK Huff, JR Vacca, JP
Citation: Bd. Dorsey et al., Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors, J MED CHEM, 43(18), 2000, pp. 3386-3399
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
Authors: Condra, JH Petropoulos, CJ Ziermann, R Schleif, WA Shivaprakash, M Emini, EA
Citation: Jh. Condra et al., Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy, J INFEC DIS, 182(3), 2000, pp. 758-765
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
Authors: Gulick, RM Mellors, JW Havlir, D Eron, JJ Meibohm, A Condra, JH Valentine, FT McMahon, D Gonzalez, C Jonas, L Emini, EA Chodakewitz, JA Isaacs, R Richman, DD
Citation: Rm. Gulick et al., 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine, ANN INT MED, 133(1), 2000, pp. 35-39
Risultati: 1-13 |